Introduction
Establishing a biomarker as an eff ective surrogate, something measureable now but indicative of some later important clinical event, is both important and diffi cult. Th e often-quoted ideal of a surrogate marker is the blood cholesterol level. We know that if this level is elevated, there is an increased risk of future serious cardiovascular harm, including death, and that reducing cholesterol levels reduces that risk of serious harm. For example, the Scandinavian Simvastatin Survival Study randomised patients with clinically established coronary heart disease to 5 years of simvastatin or placebo [1] . Th e statin produced signi fi cant and large reductions in blood lipids, as well as a 24% reduction in coronary mortality over 10 years, but with a number-needed-to-treat of about 50, meaning that there were 2% fewer coronary deaths when a statin was used [2] .
In 2001 a National Institutes of Health working group defi ned surrogacy based on prediction of a more serious outcome from epidemiologic, therapeutic, pathophysiologic or other scientifi c evidence [3] : • A biological marker (biomarker) is a characteristic that is objectively measured and evaluated as an indicator of normal biologic processes, pathogenic processes or pharmacologic responses to a therapeutic intervention. • A clinical endpoint is a characteristic or variable that refl ects how a patient feels, functions or survives. • A surrogate endpoint is a biomarker that is intended to substitute for a clinical endpoint. A surrogate endpoint is expected to predict clinical benefi t (or harm, or lack of benefi t or harm) based on epidemiologic, thera peutic, pathophysiologic or other scientifi c evidence. A more recent publication by the Institute of Medicine of the National Academy of Sciences has examined how biomarkers may be evaluated for eff ective use in chronic disease [4] . Th is document argues that the biomarker evaluation process should consist of three steps: 1. Analytical validation: analyses of available evidence on the analytical performance of an assay. 2. Qualifi cation: assessment of available evidence on associations between the biomarker and disease states, including data showing eff ects of interventions on both the biomarker and clinical outcomes. 3. Utilisation: contextual analysis based on the specifi c use proposed and the applicability of available evidence to this use. Th is analysis includes a determination of whether the validation and qualifi cation conducted provide suffi cient support for the use proposed.
Abstract
The characteristic of a biomarker that makes it a useful surrogate is the ability to identify a high risk of clinically important benefi ts or harms occurring in the future. A number of defi nitions or descriptions of surrogate defi nition have been put forward. Most recently the Institute of Medicine of the National Academy of Sciences in the USA has put forward an evaluation scheme for biomarkers, looking at validation (assay performance), qualifi cation (assessment of evidence), and utilisation (the context in which the surrogate is to be used). This paper examines the example of endoscopy as a surrogate marker of NSAID-induced mucosal damage using the Institute of Medicine criteria. The article fi nds extensive evidence that the detection of endoscopic ulcers is a valid marker. The process of qualifi cation documents abundant evidence showing that endoscopic ulcers and serious upper gastrointestinal damage are infl uenced in the same direction and much the same magnitude by a variety of risk factors and interventions. Criticisms of validation and qualifi cation for endoscopic ulcers have been examined, and dismissed. Context is the key, and in the context of serious NSAID-induced upper gastrointestinal harm, endoscopic ulcers represent a useful surrogate. Generalisability beyond this context is not considered.
Th e document is mainly aimed at determining how the US Food and Drug Administration should consider evidence around the use of biomarkers or surrogates. Th e publication has tested the methodology on several possible surrogates: tumour size for cancer, C-reactive protein, troponin, β-carotene, and low-density and highdensity lipoprotein for cardiovascular risk. Th e message from each case study is that context is the key; utility for one purpose may well not mean utility for all.
For low-density lipoprotein cholesterol, 'the high proba bility that lowering LDL [low-density lipoprotein] for several interventions decreases risk of cardiovascular disease, and LDL, although not perfect, is one of the best biomarkers for cardiovascular disease' [4] . What is important here is that the panel considered low-density lipoprotein cholesterol a useful surrogate despite the fact that benefi cial changes may occur for the surrogate in most patients, but benefi ts in terms of clinical events occur only for a few.
Determining the true value of a surrogate is not easy. Some approaches have taken a distinctly statistical approach [5, 6] . Other studies are more philosophical [7] [8] [9] . Th e message that context is the key can be read into all of the various approaches to defi ning what is a surrogate, and how to evaluate whether a putative surrogate really is one.
Th e fact that evaluation is needed can be seen from a short search of the literature demonstrating the extent of interest in surrogate endpoints. Of the (almost) 3,600 papers with surrogate in the title found using PubMed, fewer than 100 also mention validation or validity in the title or abstract. Th ose papers that did examine the validity of potential surrogate markers or markers actually used as surrogates often found the evidence lacking. For example, surrogate endpoints used in liver surgery trials were generally not validated [10] , and a simple walking test used in hypertension trials did not explain the treatment eff ect [11] .
Endoscopy for nonsteroidal anti-infl ammatory drug-induced mucosal damage
A wide-ranging systematic review evaluated the evidence that endoscopic ulcer may be a useful surrogate for more serious clinical harm from NSAIDs, and concluded that it was a strong candidate [12] . Other researchers disagreed [13] . Th is paper revisits the evidence in light of the Institute of Medicine report [4] .
It is widely believed that there is a biological progression from lesser to more severe gastrointestinal damage with NSAIDs: from dyspepsia and other gastrointestinal symptoms, through endoscopic erosion and asymptomatic ulcers detected endoscopically, to ulcer com plications (bleeding and perforation), and even to death [14, 15] . Asymptomatic ulcers can also bleed.
Endo scopic ulcers may be an early step in a biological pro gres sion from mucosal injury to symptomatic ulcer and ulcer complication. Th ese complications include the following: • Obstruction complicating peptic ulcers: this is a function of the ulcer's anatomical location in which lesions involving the pylorus are more likely to present with obstruction than those in the gastric corpus. • Perforation complicating peptic ulcers: like obstruction, this also depends on anatomical location; most perforating ulcers occur in the duodenum. • Bleeding: this is less predictable, but is increasingly seen in association with anti-thrombotic agents. • Death: with improved resuscitation and endoscopic therapy techniques, this complication largely depends on comorbidity. But while mortality from upper gastro intestinal bleeding has fallen substantially over recent years, bleeding associated with NSAIDs retains a higher mortality, above 10% [16] .
The Institute of Medicine process for valuating a surrogate marker
Th e three parts of the process involve validation, qualifi cation, and utilisation. Th ere are broad general requirements in each of these three sections; diff erent candidate markers will have diff erent characteristics, but the aims can briefl y be stated as follows:
Analytical validation
Analytical validation is as an assessment of assays for the biomarker and their measurement performance characteristics, determining the range of conditions under which the assays will give reproducible and accurate data. Coherence: the cause-and-eff ect interpretation of data should not seriously confl ict with the generally known facts of the natural history and biology of the disease. 8. Experiment: does removing the exposure lessen the eff ect? 9. Analogy: comparison between weaker and stronger evidence, or strong evidence of causality between another exposure and similar eff ect.
Utilisation
Utilisation is a contextual analysis of the available evidence about a biomarker with regard to the proposed use of the biomarker. Th is part considers how the surrogate marker will be used in very specifi c circumstances. If the circumstances change, so might the evaluation of the biomarker. In other words, a useful surrogate marker in one circumstance may not be a useful surrogate in another. Generalisation has always to be justifi ed.
Evaluating endoscopic ulcers as a surrogate marker of nonsteroidal anti-infl ammatory drug-induced mucosal damage

Analytical validation
Perhaps because endoscopy is a simple test, with the operator seeing a lesion, these methods have not been subjected to the same intense scrutiny that might have accompanied a new blood test, for instance. Th e common defi nition used has been that an endoscopic ulcer has to be a gastric or duodenal lesion ≥3 mm (sometimes ≥5 mm) with signifi cant depth, although the depth is not defi ned.
Commentators have cast doubt on the reliability of methods for detection of endoscopic ulcers [13, 18] , in part because of the paucity of data demonstrating interobserver accuracy and precision. Studies on gastro duodenal ulcer scars examined endoscopically and reporting diff erences between operators might be seen as supporting interobserver disagreement as a problem [19] . Th ere are two main lines of criticism -that experienced endoscopists disagree about whether endoscopic ulcers are real ulcers, and that there has been a shift in prevalence of endoscopic ulcers over time because of a lack of training and consistency between endoscopists.
Th e fi rst criticism [13] comes from a short abstract describing three experienced endoscopists viewing a training tape in a blinded fashion [20] . Th ere was a 100% agreement with obvious ulcers and trivial lesions. Th e endoscopists considered that only one-third of endoscopic ulcers (≥3 mm in greatest dimension, with depth) were actual ulcers. Th at is a fair criticism at one level, but in a sense it misses the point -the defi nition of an endoscopic ulcer for the purposes of acting as a surrogate need not be the same as that of a real ulcer.
Th e second criticism was that, in a systematic review of endoscopic ulcers in placebo arms of NSAID trials [21] , early studies had no endoscopic ulcers while later studies had a signifi cant rate of endoscopic ulcers, pointing to a failure of training [18] . Th e authors of the review have made their own eloquent defence [22] , but there are other powerful arguments against the criticism.
Th e main defence lies in the diff erence of two populations given placebo. One group consisted of healthy subjects, mostly in small, older short studies of 1 or 2 weeks' duration (all ≤4 weeks), and mostly, although not exclusively, using Lanza scoring of various sorts. Th e other group consisted of patients with osteoarthritis or rheumatoid arthritis, in much larger studies lasting 6 or 12 weeks, and using a variety of scoring systems to identify lesions ≥3 mm with unequivocal depth. Th e results can be seen in Figure 1 , which redraws data from the systematic review and adds data from two more recent studies [23, 24] . For healthy subjects, most studies (including most of those performed since 2000) record endoscopic ulcer prevalence rates ≤2%. For patients with arthritis, most studies (all since 1998) report prevalence rates ≥2%.
Th e picture is one of a low prevalence of 1.1% in 559 healthy subjects given placebo in short-duration studies, and a 3.8% prevalence in 2,368 patients with osteoarthritis or rheumatoid arthritis given placebo in longduration studies -typically six times longer than those for healthy subjects. Th e variability in Figure 1 is a refl ection of chance eff ects in small populations [25] , and given the small size of many of these patient groups the picture is one of consistency. Th e result for healthy subjects is similar to the 1% recorded in 619 healthy controls in northern Norway more than 20 years ago [26] .
Consistently higher incidence rates of endoscopic ulcers are seen with both coxibs (mean rate 5.1% in 4,691 patients) and a variety of diff erent NSAIDs (mean rate 17% in 3,915 patients) in individual treatment arms from clinical trials of celecoxib [27] , valdecoxib [28] , rofecoxib [29] [30] [31] , and etoricoxib [32] . Figure 2 shows the individual studies, using diff erent scales to Figure 1 , and Figure 3 shows a pooled analysis of event rates with NSAID, coxib, and placebo both with and without the presence of lowdose aspirin.
Another general criticism of endoscopic ulcer measurement relates to the usual choice of defi nition: an ulcer ≥3 mm with unequivocal depth. Th e argument is that a 3 mm ulcer is trivial, and depth may be an uncertain quantity for such a small ulcer. Fortunately at least three studies of endoscopic ulcers have reported results using both the ≥3 mm and the ≥5 mm defi nitions [29, 31, 32] . Figure 4 shows that the results for ≥5 mm were very close to those for ≥3 mm, and on average about 70% of endoscopic ulcers were ≥5 mm. Th e larger size gives the ulcers much greater relevance.
Despite a lack of formal tests for accuracy and precision for the endoscopic detection of ulcers, the weight of evidence from large amounts of data is that there is no cause for concern about the test.
Qualifi cation
A review examining endoscopic ulcers as a surrogate endpoint for bleeding ulcers has collated the evidence for qualifi cation, concluding that those factors having an eff ect on serious gastrointestinal harm (mainly bleeding ulcers) can aff ect endoscopic ulcers in the same direction and to much the same extent [12] . Table 1 summarises the consistent eff ects of various risk factors (age, previous Gastroduodenal ulcers detected endoscopically (predominantly 3 mm in largest diameter, with depth) in coxib or NSAID treatment groups at 6 or 12 weeks in patients with osteoarthritis or rheumatoid arthritis. Data from meta-analyses and randomised trials [27] [28] [29] [30] [31] [32] . Each symbol represents a treatment arm, the diameter proportional to the number of patients or subjects (inset scale). ulcer or bleeding ulcer history, Helicobacter pylori infection, and the eff ects of aspirin alone or with NSAIDs) and ulcer prevention strategies with NSAIDs (misoprostol, histamine-2 receptor antagonists, proton pump inhibitors, and coxib substitution).
For each of these factors, the evidence from randomised controlled trials, from meta-analyses of random ised controlled trials, and from observational studies demonstrates eff ects in the same direction and of similar magnitude; details are not provided here but are available from the original review [12] . Often there are several studies that provide information; and for the larger, better, studies, consis tency of fi ndings is an important feature. An example is the similar fi ndings in two metaanalyses of epidemio logical studies of the association between NSAIDs and upper gastrointestinal bleeding, one being conducted using studies in the 1990s [33] and the other using studies between 2000 and 2008 [34] . Table 2 shows the large magnitude of the increased risk (about fourfold overall) and similarity in the results.
Endoscopic ulcers and actual bleeding events can occasionally be measured together, as in one of a series of randomised trials from Hong Kong [35] [36] [37] [38] . Th ese trials were performed in similar groups of older patients (mean ages 64 to 70 years) with an endoscopically proven healed upper gastrointestinal bleeding event but who needed to continue taking NSAIDs for pain relief. Participants were randomised into diff erent treatment groups that included H. pylori eradication, NSAID plus proton pump inhibitor, celecoxib, or celecoxib plus proton pump inhibitor ( Figure 5 ). Th e primary outcome was usually recurrent gastrointestinal bleeding over 6 or 12 months. Figure 5 shows consistency in 6-month incidence rates in this population of patients in diff erent studies; three studies had consistent gastrointestinal bleeding rates of 4 to 5% for celecoxib. Recurrent bleeding rates for other therapies varied from 19% for naproxen in the absence of any eff ective gastroprotective strategy to about 6% for diclofenac plus omeprazole, and 0% for celecoxib plus omeprazole. Th is observation is interesting, of course, because it shows how diff erent strategies infl uence potentially serious harm.
Th is observation is also interesting because one of these trials measured both bleeding events and endoscopic ulcers in the same study [37] . Th e defi nition of bleeding was prespecifi ed. Th e endoscopic evaluations were carefully done: a single operator performed all endoscopic examinations in a treatment-blinded fashion to avoid between-observer variation. An ulcer was defi ned as a circumscribed mucosal break ≥5 mm in diameter with a perceptible depth. With diclofenac plus omeprazole, endoscopic ulcer incidence was 1.4 times higher than for celecoxib; the incidence of recurrent bleeds was 1.3 times higher. Th is again argues for consistent eff ects of diff erent therapies on both endoscopic ulcers and gastrointestinal bleeding events. Th is study is important for three key reasons:
• Th e study is the only one in which both the clinical outcome and surrogate marker were measured together. • Upper gastrointestinal bleeding was determined against prespecifi ed criteria. • A single operator determined the presence of gastroduodenal ulcers using a larger size than is the norm, meaning that these endoscopic ulcers were not trivial. In populations where risk of bleeding is lower, the number of bleeding events is so small that it is impractical to measure them in the same study. High-risk populations such as this off er an ethical approach to confi rming links between a putative surrogate and a clinical endpoint.
One fi nal piece of evidence linking endoscopic ulcers and bleeding events comes from an analysis of NSAIDinduced harm [14] . Th is analysis examined a number of NSAID-related outcomes, from endoscopic ulcers to clinically diagnosed ulcers, to bleeding events and to death, and demonstrated a consistent eff ect with NSAIDs for all of these outcomes over a very wide range of event rates ( Figure 6 ). Th e links at each stage of the process from symptoms such as dyspepsia, to endoscopic ulcers, to serious bleeding events, and even to death, are clear.
For example, patients taking low-dose aspirin or clopidrogel suff ering dyspepsia have a spectrum of fi ndings on endoscopic evaluation, including ulcer, erosions, and haemorrhagic spots (Figure 7 ) [39] .
Th ere do not appear to be any black swans -evidence contradicting the general fi nding that infl uences on bleeding events and endoscopic ulcers are coherent in direction and magnitude. A suggestion that sulindac, a non steroidal anti-infl ammatory prodrug, elevates bleeding events but not endoscopic ulcers is only weakly supported. Th ere is good evidence of sulindac elevating bleeding events [33] ; the evidence for a lack of eff ect on Table 1 
. Summary of the consistent eff ects of various risk factors and ulcer prevention strategies with NSAIDs
Infl uence on outcomes Eff ect on endoscopic ulcers Eff ect on upper gastrointestinal bleeding
Risk factors
Age RCTs show incidence of ulcers to increase with age, more than threefold over fi ve decades Piroxicam ≤20 mg 5.6 (4.7 to 6.7) 9.3 (7.5 to 11) Current NSAID use 4.2 (3.9 to 4.6) 4.6 (4.3 to 4.9)
Consistently large magnitude of the increased risk of upper gastrointestinal bleeding with nonsteroidal anti-infl ammatory drugs (NSAIDs) in two meta-analyses of observational studies [33, 34] . Results show the risk of use of NSAID compared with nonuse, adjusted for confounders.
endoscopic ulcers derives from one study lacking data [40] and from another on 15 healthy subjects given sulindac for 7 days [41] . Finally, the association between upper gastrointestinal endoscopic ulcers and serious clinical events is strong. A positive view on each of the nine Hill criteria can be supported by the evidence we have -and although not all is covered in this article, Table 3 summarises what we know.
Utilisation
All of the evidence put forward to justify the surrogate nature of gastroduodenal endoscopic ulcers is in the context of harm from the use of aspirin or NSAIDs. Th e use of endoscopic ulcers as a surrogate would be justifi able in the context, for example, of new preventative measures being used with established NSAIDs, especially those known already to be associated with either serious upper gastrointestinal clinical events, or endoscopic ulcer, or both. Examples would be any of the new combination products of traditional NSAID plus proton pump inhibitor, as in naproxen plus esomeprazole [42] , or NSAID plus histamine-2 receptor antagonist, as in ibuprofen plus famotidine [43] .
With increasing use of gastroprotection in the community, and guidance that gastroprotection with proton pump inhibitors should be used even with coxibs [44] , the incidence of bleeding events may fall to the point where clinical trials without gastroprotection become unethical. In Japan, a large increase in the use of proton pump inhibitors has resulted in a precipitous fall in bleeding rates, and particularly deaths from a bleeding event [45] .
Whether gastroduodenal endoscopic ulcers could justify a surrogate status in any other context could only be considered on a case-by-case basis. Each of the various stages of validation, qualifi cation, and utilisation would need to be revisited for that specifi c context, and the Hill criteria also revisited. Rate of gastroduodenal complications (events) with NSAIDs (includes aspirin) compared with control (no NSAID, or placebo, or NSAID + mucosal protection therapy) in 15 randomised controlled trials (RCTs; squares) and three cohort studies (circles). White symbols, uncomplicated peptic, gastric or duodenal ulcer; grey symbols, ulcer bleed or perforation; black symbols, death attributable to a bleeding or perforated ulcer. Several trials reported several levels of harm; that is, several events. Death outcomes in two RCTs had a control event rate of 0%; these were set a control event rate of 0.001% for graphical purposes. Dotted line, the line of equality. From [14] with permission. 
Discussion
Th is paper has sought to re-examine whether the evidence we have justifi es using gastroduodenal endoscopic ulcers as a surrogate for serious upper gastrointestinal bleeding events within the context of the use of aspirin or NSAIDs. Th e article has followed a pathway for the evaluation of biomarkers and surrogate endpoints in chronic disease, building on a previous review that predated this pathway. Two important conclusions stand out.
Th ere is a strong case for considering endoscopic ulcers as a surrogate for NSAID-induced gastrointestinal harm. Th ese are valid measurements, supported by a wealth of evidence linking endoscopic with more serious upper gastrointestinal harm, within the context of the use of aspirin or NSAIDs. Criticisms of the original fi ndings have been considered, and rejected. Th e weakness originally identifi ed -the absence of an observation of the direct progression from endoscopic ulcers to ulcer complications -remains.
Th e structure suggested in the Institute of Medicine report has provided a constructive and focused way of examining this particular example of putative surrogacy. Separating the validity of the measurement, the qualification of the evidence of association, and the context or contexts in which the assumption of surrogacy is valid represents an important methodological statement that has worked well in this case, as it did in case studies in the report.
Th e Institute of Medicine evaluation process considered that if the biomarker-clinical endpoint relationship persisted over multiple interventions, it may be thought to be more generalisable. Th e evidence of links with age, previous ulcer history, and H. pylori infection do not involve NSAIDs, and off er the prospect of generalisability to other contexts. Th is evaluation examined links with a number of risk factors and interventions, but within the context of NSAID use. Context is the key, and those other contexts require their own separate evaluations.
In the end, and despite eff orts to the contrary, decisions on whether any marker is a useful or justifi able surrogate retain an element of subjectivity or even bias. Even Austin Bradford Hill, in his infl uential 1965 address to the Royal Society of Medicine that examined diff erences between association and causation, admitted that: 'In asking for very strong evidence I would, however, repeat emphatically that this does not imply crossing every "t", and swords with every critic, before we act' [17] . Th e Institute of Medicine advice off ers a mechanism to be systematic in assessing the strength and nature of evidence before the swords come out.
Conclusion
In the context of NSAID-induced upper gastrointestinal harm, endoscopic ulcers appear to be a valid surrogate marker. Th e Institute of Medicine evaluation schema has been proven to give direction and focus to evaluating a surrogate marker.
Key messages
• Determining whether a biomarker is a useful, acceptable, or valid surrogate for a future benefi cial or harmful event is complex, has been the subject of a number of approaches, and retains a degree of subjectivity. • Surrogates are useful when they are relatively common or early in a biological pathway, but the clinical event is rare and/or late. • Th e Institute of Medicine of the National Academy of Sciences in the USA has put forward an evaluation scheme for biomarkers, looking at validation (assay performance), qualifi cation (assessment of evidence of association), and utilisation (a description of the context in which the surrogate has utility). • Th is evaluation scheme has been applied to the example of endoscopy (particularly gastroduodenal ulcers) in the context of NSAID-induced gastro intestinal harm. • Considerable evidence indicated that endoscopic ulcers were a valid measure. • Considerable evidence indicated that there was a strong association between endoscopic ulcers and serious gastrointestinal harm, with a variety of risk factors and interventions infl uencing them in the same direction and with a similar magnitude. • In the context of NSAID-induced upper gastro intestinal harm, endoscopic ulcers appear to be a valid surrogate marker. • Th e Institute of Medicine evaluation schema proved to give direction and focus to evaluating a surrogate marker.
Abbreviations NSAID, nonsteroidal anti-infl ammatory drug.
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